ADIM Business Summary

Adimmune Corporation (4142.TW) is a premier biopharmaceutical manufacturer specializing in the research, development, and large-scale production of human vaccines, primarily generating revenue through national immunization contracts and international export sales. The company’s business is structured around three core segments: its flagship influenza vaccine portfolio (including EU-GMP and US-FDA certified quadrivalent shots), a specialized line of Japanese encephalitis and tetanus vaccines, and a rapidly expanding Contract Development and Manufacturing Organization (CDMO) division. By 2026, Adimmune has strategically pivoted toward high-volume CDMO services for global partners, aiming for a total shipment capacity of 100 million doses to diversify revenue streams beyond seasonal flu cycles. In the competitive landscape, Adimmune maintains a dominant domestic position against local rivals like Medigen Vaccine Biologics and TTY Biopharm, while competing globally with multinational giants such as Sanofi and GlaxoSmithKline (GSK) by leveraging its unique status as the only Asian vaccine facility with dual US and EU certifications. The company is led by Chairman and CEO Chi-Hsien (Steve) Chan, a distinguished physician and former Minister of Health and Welfare for Taiwan, whose political and medical pedigree has been instrumental in securing government partnerships and international regulatory approvals. Supporting him is President Chung-Cheng (T.C.) Liu, an industry veteran who oversees the technical integration of the company’s cell-culture and egg-based manufacturing platforms. The executive team also includes Chief Operating Officer Chin-Chuan Chang and Executive Vice President Vic Chang, who manage the company's strategic shift toward global CDMO dominance. Founded in 1965 and headquartered in Taichung, Adimmune benefits from a stable institutional investor base, most notably the Taiwan National Development Fund and Diamond BioFund, which underscore its role as a critical asset in Taiwan’s national biosecurity infrastructure.